BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17549653)

  • 21. Global benefit-risk assessment in designing clinical trials and some statistical considerations of the method.
    Pritchett YL; Tamura R
    Pharm Stat; 2008; 7(3):170-8. PubMed ID: 17538942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating the number needed to treat (NNT) index when the data are subject to error.
    Walter SD; Irwig L
    Stat Med; 2001 Mar; 20(6):893-906. PubMed ID: 11252011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relative risk, absolute risk and number needed to treat: basic concepts.
    Carneiro AV
    Rev Port Cardiol; 2009 Jan; 28(1):83-7. PubMed ID: 19388495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The number needed to treat (NNT)].
    Richard T; Vanhaeverbeek M; Van Meerhaeghe A
    Rev Med Brux; 2011; 32(5):453-8. PubMed ID: 22165523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compelling or irrelevant? Using number needed to treat can help decide.
    Citrome L
    Acta Psychiatr Scand; 2008 Jun; 117(6):412-9. PubMed ID: 18479317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absolute risk reductions, relative risks, relative risk reductions, and numbers needed to treat can be obtained from a logistic regression model.
    Austin PC
    J Clin Epidemiol; 2010 Jan; 63(1):2-6. PubMed ID: 19230611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The number needed to treat needs an associated odds estimation.
    Aino H; Yanagisawa S; Kamae I
    J Public Health (Oxf); 2004 Mar; 26(1):84-7. PubMed ID: 15044581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Number needed to treat: a useful tool for estimating the effectiveness of a treatment].
    van Harten PN
    Tijdschr Psychiatr; 2008; 50(6):337-43. PubMed ID: 18548411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Communicating benefit and risk.
    Baglin T
    Br J Haematol; 2009 Jun; 146(1):31-3. PubMed ID: 19438473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to deal with measures of association: a short guide for the clinician.
    Knol MJ; Algra A; Groenwold RH
    Cerebrovasc Dis; 2012; 33(2):98-103. PubMed ID: 22156574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Making sense of odds and odds ratios.
    Grimes DA; Schulz KF
    Obstet Gynecol; 2008 Feb; 111(2 Pt 1):423-6. PubMed ID: 18238982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Ketter TA
    Int J Clin Pract; 2013 May; 67(5):407-11. PubMed ID: 23574101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimates of absolute cause-specific risk in cohort studies.
    Benichou J; Gail MH
    Biometrics; 1990 Sep; 46(3):813-26. PubMed ID: 2242416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introduction--databases and the assessment of complications associated with the treatment of patients with congenital cardiac disease.
    Jacobs JP
    Cardiol Young; 2008 Dec; 18 Suppl 2():1-37. PubMed ID: 19063774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Number needed to treat is incorrect without proper time-related considerations.
    Suissa D; Brassard P; Smiechowski B; Suissa S
    J Clin Epidemiol; 2012 Jan; 65(1):42-6. PubMed ID: 21816576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The number needed to treat as a measure of effect in the treatment of primary immune thrombocytopenia].
    Vizcaíno G; Vizcaíno-Carruyo J
    Invest Clin; 2012 Mar; 53(1):16-27. PubMed ID: 22524105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells.
    Rücker G; Schwarzer G; Carpenter J; Olkin I
    Stat Med; 2009 Feb; 28(5):721-38. PubMed ID: 19072749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention. How much harm? How much benefit? 1. Influence of reporting methods on perception of benefits.
    Marshall KG
    CMAJ; 1996 May; 154(10):1493-9. PubMed ID: 8624999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Risk and prevention in cardiovascular diseases].
    Gulácsi L; Edes I; Hajdú E; Tóthfalusi L
    Orv Hetil; 2004 Dec; 145(50):2515-21. PubMed ID: 15662751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Statistical notes. Absolute and relative effect measures].
    Marubini E; Reina G
    Ital Heart J Suppl; 2004 Jun; 5(6):466-71. PubMed ID: 15471151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.